Profile
Neil M.
Frazer is the founder of DMK Pharmaceuticals Corp.
(Old).
He worked as a Chief Medical Officer at Chimerix, Inc. and OncoSil Medical Ltd.
He also served as a Non-Executive Director & Chief Medical Officer at Immutep Ltd.
Mr. Frazer completed his undergraduate degree at The University of Edinburgh.
Former positions of Neil M. Frazer
| Companies | Position | End |
|---|---|---|
| ONCOSIL MEDICAL LIMITED | Chief Executive Officer | 2014-09-08 |
DMK Pharmaceuticals Corp. (Old)
 DMK Pharmaceuticals Corp. (Old) BiotechnologyHealth Technology DMK Pharmaceuticals Corp. (Old) was an American commercial stage neuro-biotech company that focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders. The company's approved products included Zimhi® (naloxone) injection for the treatment of opioid overdose and Symjepi® (epinephrine) injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company was founded by Neil M. Frazer and Ebrahim Versi. DMK Pharmaceuticals Corp. was acquired by DMK Pharmaceuticals Corp. on May 25, 2023 for $27 million. | Founder | - |
| IMMUTEP LIMITED | Chief Tech/Sci/R&D Officer | - |
| CHIMERIX, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Neil M. Frazer
| The University of Edinburgh | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| IMMUTEP LIMITED | Health Technology |
| ONCOSIL MEDICAL LIMITED | Health Technology |
| Private companies | 1 |
|---|---|
DMK Pharmaceuticals Corp. (Old)
DMK Pharmaceuticals Corp. (Old) BiotechnologyHealth Technology DMK Pharmaceuticals Corp. (Old) was an American commercial stage neuro-biotech company that focused on developing and commercializing products for the treatment of opioid overdose and substance use disorders. The company's approved products included Zimhi® (naloxone) injection for the treatment of opioid overdose and Symjepi® (epinephrine) injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company was founded by Neil M. Frazer and Ebrahim Versi. DMK Pharmaceuticals Corp. was acquired by DMK Pharmaceuticals Corp. on May 25, 2023 for $27 million. | Health Technology |
- Stock Market
- Insiders
- Neil M. Frazer